Faculty

Matthew John Atherton, BVSc, MVM, PhD

Graduate Group Affiliations

Contact information

Email:
mattath@upenn.edu

Publications

Search PubMed for articles

Education:
BVSc (Veterinary Medicine)
University of Bristol, 2005.
PhD (Medical Sciences-Infection & Immunity)
McMaster University , 2017.

Links
Search PubMed for articles

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Clinical Expertise

Medical oncology

Description of Research Expertise

Defining the prognostic and therapeutic role of T cells in hematologic neoplasms utilizing a multi-species comparative approach. Identification and appraisal of novel targets for T cell-based immunotherapy in clinical trials of canine patients with spontaneous and aggressive tumors bearing translational importance for human oncology.

Selected Publications

Zhang, H., Yu, P., Tomar, V. S., Chen, X., Atherton, M. J., Lu, Z., Zhang, H. G., Li, S., Ortiz, A., Gui, J., Leu, N. A., Yan, F., Blanco, A., Meyer-Ficca, M. L., Meyer, R. G., Beiting, D. P., Li, J., Nunez-Cruz, S., O'Connor, R. S., Johnson, L. R., Minn, A. J., George, S. S., Koumenis, C., Diehl, J. A., Milone, M. C., Zheng, H., Fuchs, S. Y.: Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nat Cancer 3(7): 808-820, 2022.

Atherton, M. J., Mason, N. J.: Bite-size introduction to canine hematologic malignancies. Blood Adv 6(13): 4073-4084, 2022.

Atherton, M. J., Rotolo, A., Haran, K. P., Mason, N. J.: Case report: clinical and serological hallmarks of cytokine release syndrome in a canine B cell lymphoma patient treated with autologous CAR-T cells. Front Vet Sci 9: 824982, 2022.

Gedney, A., Salah, P., Mahoney, J. A., Krick, E., Martins, R., Scavello, H., Lenz, J. A., Atherton, M. J.: Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I''m-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma. Veterinary and Comparative Oncology 20(3): 688-696, 2022.

Lenz, J. A., Assenmacher, C. A., Costa, V., Louka, K., Rau, S., Keuler, N. S., Zhang, P. J., Maki, R. G., Durham, A. C., Radaelli, E., Atherton, M. J.: Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma. Cancer Immunology, Immunotherapy 2021.

Rotolo, A., Atherton, M. J., Kasper, B. T., Haran, K. P., Mason, N. J.: Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer. STAR Protoc 2(4): 100905, 2021.

LeBlanc, A. K., Atherton, M., Bentley, R. T., Boudreau, C. E., Burton, J. H., Curran, K. M., Dow, S., Giuffrida, M. A., Kellihan, H. B., Mason, N. J., Oblak, M., Selmic, L. E., Selting, K. A., Singh, A., Tjostheim, S., Vail, D. M., Weishaar, K. M., Berger, E. P., Rossmeisl, J. H., Mazcko, C.: Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Veterinary and Comparative Oncology 19(2): 311-352, 2021.

Benjamin, S. E., Sorenmo, K. U., Krick, E. L., Salah, P., Walsh, K. A., Weinstein, N. M., Keuler, N. S., Avery, A. C., Atherton, M. J., Lenz, J. A.: Response-based modification of CHOP chemotherapy for canine B-cell lymphoma. Veterinary and Comparative Oncology 19(3): 541-550, 2021.

Pol, J. G., Atherton, M. J., Stephenson, K. B., Bridle, B. W., Workenhe, S. T., Kazdhan, N., McGray, A. R., Wan, Y., Kroemer, G., Lichty, B. D.: Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. J Immunother Cancer 8(2), 2020.

Panjwani, M. K., Atherton, M. J., MaloneyHuss, M. A., Haran, K. P., Xiong, A., Gupta, M., Kulikovsaya, I., Lacey, S. F., Mason, N. J.: Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. Oncoimmunology 9(1): 1676615, 2020.

Atherton, M. J., Lenz, J. A., Mason, N. J.: Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy? Veterinary and Comparative Oncology 18(4): 447-470, 2020.

Pol, J. G., Acuna, S. A., Yadollahi, B., Tang, N., Stephenson, K. B., Atherton, M. J., Hanwell, D., El-Warrak, A., Goldstein, A., Moloo, B., Turner, P. V., Lopez, R., LaFrance, S., Evelegh, C., Denisova, G., Parsons, R., Millar, J., Stoll, G., Martin, C. G., Pomoransky, J., Breitbach, C. J., Bramson, J. L., Bell, J. C., Wan, Y., Stojdl, D. F., Lichty, B. D., McCart, J. A.: Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology 8(1): e1512329, 2019.

Pol, J. G., Atherton, M. J., Bridle, B. W., Stephenson, K. B., Le Boeuf, F., Hummel, J. L., Martin, C. G., Pomoransky, J., Breitbach, C. J., Diallo, J. S., Stojdl, D. F., Bell, J. C., Wan, Y., Lichty, B. D.: Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virother 7: 117-128, 2018.

Atherton, M. J., Stephenson, K. B., Tzelepis, F., Bakhshinyan, D., Nikota, J. K., Son, H. H., Jirovec, A., Lefebvre, C., Dvorkin-Gheva, A., Ashkar, A. A., Wan, Y., Stojdl, D. F., Belanger, E. C., Breau, R. H., Bell, J. C., Saad, F., Singh, S. K., Diallo, J. S., Lichty, B. D.: Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncoimmunology 7(7): e1445459, 2018.

Atherton, M. J., Stephenson, K. B., Nikota, J. K., Hu, Q. N., Nguyen, A., Wan, Y., Lichty, B. D.: Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine 36(16): 2181-2192, 2018.